Orion Corporation Announces Important Manager Transactions
Orion Corporation is thrilled to share significant updates regarding transactions executed by key management personnel, specifically Satu Ahomäki. This news is part of our ongoing commitment to transparency as outlined under the Market Abuse Regulation (EU) No 596/2014, ensuring all stakeholders are informed about important corporate developments.
Details of the Transactions
On a notable date, an initial notification was made concerning transactions with shares associated with Orion Corporation. Satu Ahomäki, an esteemed other senior manager, played a pivotal role in this transaction.
In total, two substantial disposals were recorded under her management services, indicating robust trading activity. The transactions occurred through NASDAQ HELSINKI LTD, ensuring compliance with all necessary regulations surrounding trading operations.
Transaction Specifics
The first significant transaction, which took place on the fourth of August, involved the disposal of 2205 shares at a consistent unit price of 70.7 EUR. This transaction was notable for being executed seamlessly in accordance with Orion’s guidelines and the regulatory frameworks established within the trading venues.
Further details revealed additional disposals, further enhancing our engagement with the market. The aggregation shows a total volume for that day at a weighted average price maintaining stability in the trading environment, emphasizing the strategic direction of Orion Corporation.
Company Overview
Orion Corporation is a leading Nordic pharmaceutical enterprise with deep-rooted values focused on enhancing health and well-being for more than a century. Our reach extends globally, providing a diverse array of human and veterinary pharmaceuticals alongside active pharmaceutical ingredients. Our dedication has fostered a rich portfolio, including proprietary and generic medicines along with consumer health offerings.
Strategic Focus and Core Areas
Our core therapeutic areas concentrate heavily on oncology and pain management, developing groundbreaking proprietary products to combat complex health challenges. The products pioneered by Orion effectively treat various conditions such as cancer, neurological disorders, and respiratory ailments, representing our commitment to innovation in healthcare.
In 2024, with net sales reaching an impressive EUR 1,542 million, Orion Corporation proudly employed around 3,700 professionals committed to fostering better health outcomes worldwide. Our shares are publicly traded on Nasdaq Helsinki, allowing us to uphold a high standard of accountability to our stakeholders.
Contact Information
If you require further information or have questions regarding this announcement, please feel free to reach out to:
Liisa Hurme
President and CEO
Orion Corporation
Orionintie 1A, FI-02200 Espoo, Finland
Frequently Asked Questions
What transactions were reported by Orion Corporation?
Orion Corporation reported share disposals made by Satu Ahomäki, totaling volumes of 2205 and 795 shares at a unit price of 70.7 EUR.
What is the position of Satu Ahomäki in the company?
Satu Ahomäki is identified as an other senior manager within Orion Corporation, therefore holding significant responsibilities in management activities.
Where are Orion Corporation's shares listed?
Orion Corporation’s shares are listed on Nasdaq Helsinki, making it accessible for interested investors.
What sectors does Orion Corporation focus on?
The primary focus areas for Orion Corporation include oncology and pain management, alongside developing medications for various health conditions.
How many employees does Orion Corporation have?
Orion Corporation employs approximately 3,700 professionals worldwide, dedicated to enhancing well-being across the globe.
